The DOI matches its Crossref record, with a small difference in title or year; 34 of the 34 references it cites were found in a registry or an index.
A Clinical Trial of Vena Caval Filters in the Prevention of Pulmonary Embolism in Patients with Proximal Deep-Vein Thrombosis
Open accessAbstract
BACKGROUND: The efficacy and safety of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis is still a matter of debate. METHODS: Using a two-by-two factorial design, we randomly assigned 400 patients with proximal deep-vein thrombosis who were at risk for pulmonary embolism to receive a vena caval filter (200 patients) or no filter (200 patients), and to receive low-molecular-weight heparin (enoxaparin, 195 patients) or unfractionated heparin (205 patients). The rates of recurrent venous thromboembolism, death, and major bleeding were analyzed at day 12 and at two years. RESULTS: At day 12, two patients assigned to receive filters (1.1 percent), as compared with nine patients assigned to receive no filters (4.8 percent), had had symptomatic or asymptomatic pulmonary embolism (odds ratio, 0.22; 95 percent confidence interval, 0.05 to 0.90). At two years, 37 patients assigned to the filter group (20.8 percent), as compared with 21 patients assigned to the no-filter group (11.6 percent), had had recurrent deep-vein thrombosis (odds ratio, 1.87; 95 percent confidence interval, 1.10 to 3.20). There were no significant differences in mortality or the other outcomes. At day 12, three patients assigned to low-molecular-weight heparin (1.6 percent), as compared with eight patients assigned to unfractionated heparin (4.2 percent), had had symptomatic or asymptomatic pulmonary embolism (odds ratio, 0.38; 95 percent confidence interval, 0.10 to 1.38). CONCLUSIONS: In high-risk patients with proximal deep-vein thrombosis, the initial beneficial effect of vena caval filters for the prevention of pulmonary embolism was counterbalanced by an excess of recurrent deep-vein thrombosis, without any difference in mortality. Our data also confirmed that low-molecular-weight heparin was as effective and safe as unfractionated heparin for the prevention of pulmonary embolism.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We identified 7 systematic reviews 223-229 and 2 randomized trials 230,231 (n 5 799).”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [230]
In the citing paper
“The PREPIC 230 trial included 400 patients with proximal DVT with or without concomitant PE. Participants were randomized to insertion of a nonretrievable IVC filter in addition to anticoagulation or to anticoagulation alone. Patients were followed for 2 years.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [230]
Citations
Cites
Antithrombotic Therapy for Venous Thromboembolic Disease
Hyers, T. M., Agnelli, G., Hull, R. D., Morris, T. A., Samama, M., Tapson, V., & Weg, J. G. (2001) · Chest · doi:10.1378/chest.119.1_suppl.176s · Cited by 2,042
Low-Molecular-Weight Heparin in the Treatment of Patients with Venous Thromboembolism
(1997) · New England Journal of Medicine · doi:10.1056/nejm199709043371001 · Cited by 784
Hull, R. D., Raskob, G. E., Hirsh, J., Jay, R. M., Leclerc, J. R., Geerts, W. H., Rosenbloom, D., Sackett, D. L., Anderson, C., Harrison, L., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198610303151801 · Cited by 722
Basu, D., Gallus, A., Hirsh, J., & Cade, J. (1972) · New England Journal of Medicine · doi:10.1056/nejm197208172870703 · Cited by 661
Hirsh, J., & Hoak, J. (1996) · Circulation · doi:10.1161/01.cir.93.12.2212 · Cited by 635
Heparin for 5 Days as Compared with 10 Days in the Initial Treatment of Proximal Venous Thrombosis
Hull, R. D., Raskob, G. E., Rosenbloom, D., Panju, A. A., Brill-Edwards, P., Ginsberg, J. S., Hirsh, J., Martin, G. J., & Green, D. (1990) · New England Journal of Medicine · doi:10.1056/nejm199005033221802 · Cited by 505
Brandjes, D. P. M., Heijboer, H., Büller, H. R., de Rijk, M., Jagt, H., & ten Cate, J. W. (1992) · New England Journal of Medicine · doi:10.1056/nejm199211193272103 · Cited by 480
(1990) · JAMA · doi:10.1001/jama.263.20.2753 · Cited by 376
Inferior Vena Cava Filters: Indications, Safety, Effectiveness
Becker, D. M. (1992) · Archives of Internal Medicine · doi:10.1001/archinte.1992.00400220023005 · Cited by 360
Research works printed but not linked: 7
- Greenfield LJ, 1988, Surgery, 104, 706
- Greenfield LJ, 1996, Semin Vasc Surg, 9, 50
- Alexander JJ, 1986, Surg Gynecol Obstet, 163, 405
- Fink JA, 1991, Surg Gynecol Obstet, 172, 253
- Cohen JR, 1991, Surgery, 109, 12
- Golueke PJ, 1988, Surgery, 103, 111
- Byar DP, 1985, Cancer Treat Rep, 69, 1055
Cited by
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
Prevention of Venous Thromboembolism
Geerts, W. H., Pineo, G. F., Heit, J. A., Bergqvist, D., Lassen, M. R., Colwell, C. W., & Ray, J. G. (2004) · Chest · doi:10.1378/chest.126.3_suppl.338s · Cited by 5,895
Konstantinides, S. V., Meyer, G., Becattini, C., Bueno, H., Geersing, G.-J., Harjola, V.-P., Huisman, M. V., Humbert, M., Jennings, C. S., Jiménez, D., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz405 · Cited by 4,916
Antithrombotic Therapy for VTE Disease
Kearon, C., Akl, E. A., Ornelas, J., Blaivas, A., Jimenez, D., Bounameaux, H., Huisman, M., King, C. S., Morris, T. A., Sood, N., et al. (2016) · Chest · doi:10.1016/j.chest.2015.11.026 · Cited by 4,830
Prevention of Venous Thromboembolism
Geerts, W. H., Heit, J. A., Clagett, G. P., Pineo, G. F., Colwell, C. W., Anderson, F. A., & Wheeler, H. B. (2001) · Chest · doi:10.1378/chest.119.1_suppl.132s · Cited by 4,373
Metadata
- Authors
- Decousus, H., Leizorovicz, A., Parent, F., Page, Y., Tardy, B., Girard, P., Laporte, S., Faivre, R., Charbonnier, B., Barral, F.-G., Huet, Y., & Simonneau, G.
- Affiliations
- Hôpital Antoine-Béclère (FR)
- Institute Mutualiste Montsouris (FR)
- Centre Hospitalier Universitaire de Saint-Étienne (FR)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1998-02-12
- Volume
- 338
- Issue
- 7
- Pages
- 409-416
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2312814626
- Cited by
- 1,702
- References
- 34
- Citations by year
- 2026: 24 · 2025: 21 · 2024: 31 · 2023: 29 · 2022: 39 · 2021: 45 · 2020: 55 · 2019: 43 · 2018: 52 · 2017: 59 · 2016: 72 · 2015: 59 · 2014: 69 · 2013: 86 · 2012: 75
- FWCI
- 46.03
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cardiovascular and Diving-Related Complications
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Keywords
- vena caval filters, pulmonary embolism prevention, proximal deep vein thrombosis, low molecular weight heparin, enoxaparin, unfractionated heparin, recurrent deep vein thrombosis, venous thromboembolism, major bleeding, mortality
- MeSH terms
- Aged, Anticoagulants, Combined Modality Therapy, Female, Hemorrhage, Heparin, Humans, Male, Pulmonary Embolism, Recurrence, Thrombophlebitis, Survival Analysis, Vena Cava Filters, Treatment Outcome, Enoxaparin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Clinical Trial of Vena Caval Filters in the Prevention of Pulmonary Embolism in Patients with Proximal Deep-Vein Thrombosis. https://app.cochat.ai/papers/10.1056/nejm199802123380701
- The paper
- Decousus, H., Leizorovicz, A., Parent, F., Page, Y., Tardy, B., Girard, P., Laporte, S., Faivre, R., Charbonnier, B., Barral, F.-G., Huet, Y., & Simonneau, G. (1998). A Clinical Trial of Vena Caval Filters in the Prevention of Pulmonary Embolism in Patients with Proximal Deep-Vein Thrombosis. New England Journal of Medicine. https://doi.org/10.1056/nejm199802123380701
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.